STOCK TITAN

BridgeBio Pharma: Trust proposes $2.34M stock sale

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
144

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. (BBIO) common stock is the subject of the Kumar Haldea Family Irrevocable Trust’s proposed sale of 30,000 common shares, with an aggregate market value of $2,340,300 and an approximate sale date of November 19, 2026. The form lists 194,800,782 common shares outstanding. Neil Kumar is identified as a director and officer.

Shares proposed for sale 30,000 shares Kumar Haldea Family Irrevocable Trust; approximate sale date November 19, 2026
Aggregate market value $2,340,300 Proposed sale by Kumar Haldea Family Irrevocable Trust
Common shares outstanding 194,800,782 shares Count listed in the securities information
Rule 10b5-1 plan adoption or instruction date May 13, 2026 Date listed for reliance on Rule 10b5-1
Rule 10b5-1 regulatory
"If Relying on Rule 10b5-1"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
Conversion Management Incentives Units financial
"Nature of Acquisition Transaction: Conversion Management Incentives Units"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BBIO shares does the Kumar Haldea Family Irrevocable Trust propose to sell?

The trust proposes to sell 30,000 common shares, with an aggregate market value of $2,340,300 and an approximate sale date of November 19, 2026.

What is the Rule 10b5-1 plan date for the proposed BBIO sale?

The notice lists May 13, 2026 as the plan adoption or instruction date for reliance on Rule 10b5-1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading